PBPiet Erik Beusker

Piet Erik Beusker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piet Erik Beusker has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity

    by Matthias Bleeke, Arne Simon, Beate Winkler, Sabine Heine, Anna Eichinger, Ulrich von Both, Meinolf Siepermann, Sonya El Amouri, Arndt Borkhardt, Yvonne Pritschow, et al.

    Summary: In patients with sickle cell disease (SCD), parvovirus B19 infection (B19V) leads to acute anaemia (aplastic crisis), but may also be associated with other serious complications. We retrospectively analysed clinical data from paediatric SCD patients with B19V infections between 2023 and 2025, including symptoms, laboratory parameters, diagnostic procedures and treatment details to detect differences between SCD genotypes (HbSS and HbS/β 0 ‐thalassaemia, i.e. HbSS/Sβ 0 , and HbSC) and to determine the effect of hydroxyurea (HU; hydroxycarbamide) treatment in HbSS/Sβ 0 patients. Ninety‐eight patients (76 HbSS/Sβ 0 , 22 HbSC) were included in the study. There were significant differences in the symptoms of infection between genotypes, with a high prevalence of back pain as well as higher C‐reactive protein and lactate dehydrogenase levels in HbSC. HbSC patients also received chest X‐ray more frequently and required longer inpatient treatment. In addition, HbSC patients showed a significantly higher rate of immunoglobulin G seroconversion at the onset of symptoms, suggesting that antibody formation influences clinical appearance. In HbSS/Sβ 0 patients, HU treatment was associated with higher haemoglobin and reduced transfusion requirements, but more frequently with neutropenia. In summary, B19V infections induce different clinical presentations depending on SCD genotypes, with HbSC patients showing a distinct phenotypic presentation. HU treatment reduces the need for transfusions in patients with HbSS/Sβ 0 .

  • Open Access

    Tick-borne tularaemia as a differential diagnosis in ulcerative skin infection and regional lymphadenopathy in children: a case report

    by Piet Erik Beusker, Karen Schonhofen, Kerstin Landwehr, Eckard Hamelmann, Janina Soler Wenglein

    Background: Tularaemia is a rare but re-emergent zoonosis in Germany, which reached a new peak in incidence in 2024. The infection rate of ticks in Germany with Francisella tularensis is only about 8% and the transmission of a clinically apparent infection by blood-sucking arthropods such as ticks, mosquitoes or horseflies accounts for about 30% of the infection routes in humans. Arthropod-borne tularaemia mainly presents as the glandular or ulceroglandular form. Delayed diagnosis and initiation of treatment with associated increased risk of complications are common. Those complications may include necrotizing abscess formation in up to 65% of cases. To our knowledge, only two cases of tularaemia following tick bites in children in Germany have been published to date. Both report cases of glandular tularaemia. The present case is therefore the first report of a clinically compatible, serology-supported presumptive case of ulceroglandular tularaemia following a tick bite in a child in Germany. It underscores the increasing relevance of tularaemia as a differential diagnosis in ulcerative skin lesions with regional lymphadenopathy. Case presentation: In the present clinical case, a 3-year-old white German boy presented with ulcerative skin infection, regional lymphadenopathy and fever following a tick bite. Calculated treatment with intravenous ampicill in and clindamycin as well as topical antiseptics initially did not result in lasting clinical improvement. In the course of typical clinical symptoms and indirect pathogen detection by serology, ulceroglandular tularaemia was assumed and appropriate oral treatment with ciprofloxacin was initiated, under which the symptoms resolved fast and completely. Conclusion: The combination of increasing incidence rates, often delayed diagnosis, and therefore high complication rates underscores the clinical relevance of this case, which highlights the growing importance of tularaemia as a differential diagnosis in ulcerative skin lesions with regional lymphadenopathy.

  • Open Access

    Optimized workup of lymph nodes in regard to UICC classification of colorectal carcinoma

    by Moritz Rust, Nabih Farkouh, Piet Beusker, Ali Eissing‐Al‐Mukahal, Clara Böker, Julian Mall, Ludwig Wilkens

    Aims: Treatment and outcomes in colorectal carcinoma (CRC) depend on the UICC classification, depth of invasion, and distant metastases. However, it is not clear whether an extensive workup of lymph nodes (LNs) is important for the adequate determination of metastases. Therefore, we compared the number of LNs and metastases obtained by a standard protocol (SP) and an extended protocol (EP) in two series with a total of 105 CRC cases and 2417 LNs. Methods and results: In the first series, the EP included complete stepwise sectioning of all LN‐bearing paraffin blocks in each case, increasing the total number of LNs from 1247 in the SP to 1333 in the EP and the number of metastases from 69 to 80. One pTNM pN1a case became pN1b, and two pN1b cases became pN2a. The staging, and thus the therapy, changed in none of them. Furthermore, no relevant effect of embedding one versus both halves of large LNs >5 mm was evident. In the second series, the EP included immunohistochemical staining for pan‐cytokeratin (monoclonal antibodies AE1/AE3) of all LN‐bearing paraffin blocks in a given case. The number of detected metastases rose from 82 to 89, with a constant total 1084 LNs. In two cases, the pTNM classification changed from pN2a to pN2b. Staging and therapy changed in none. Conclusion: An extensive workup of LNs is not mandatory in patients with CRC. A straightforward protocol is sufficient to guide clinicians to the appropriate therapy.

  • High Anion Gap Metabolic Acidosis (HAGMA) After Levetiracetam Administration in an 11-Year-Old Boy With Laminin-α2-Deficiency-Associated Muscular Dystrophy and Epilepsy

    by Piet Erik Beusker, Doortje Marieke Mehrtens, Eckard Hamelmann, Georg Classen

    Congenital muscular dystrophy type 1A (MDC1A), an autosomal recessive disorder, is one of the most prevalent forms of congenital muscular dystrophy, characterized by the loss of Laminin-α 2 subunit (Merosin). Approximately one-third of affected patients experience epileptic seizures, typically manifesting around 8 years of age, with focal onset and secondary generalization, often with tonic-clonic semiology. Most reported cases show limited or no response to conventional treatment, though a subset responds to valproate or lamotrigine. The efficacy of levetiracetam in these patients remains insufficiently studied. Metabolic acidosis is not listed as a known adverse effect of levetiracetam in the medication’s technical information. In this case, an 11-year-old male with MDC1A presented with nocturnal seizure equivalents and was started on levetiracetam therapy. Approximately 24 hours after receiving the loading dose, the patient’s condition deteriorated significantly, and severe metabolic acidosis with an elevated anion gap was observed. The patient required transfer to the pediatric intensive care unit and received intensive intravenous hydration and potassium supplementation. Upon discontinuation of levetiracetam, the patient stabilized, and metabolic normalization was achieved within approximately 24 hours. There are very few reports in the literature that also point to the development of a high anion gap metabolic acidosis after levetiracetam administration. The underlying mechanism is hypothesized but not experimentally verified, and a causal relationship remains unproven. Nevertheless, this observation represents a potentially serious adverse event associated with a commonly used medication, warranting heightened clinical awareness. We therefore recommend actively highlighting this and considering safety monitoring based on the individual risk of the patients being treated.